(al KAF ta deen)
Allergic conjunctivitis: Prevention of itching associated with allergic conjunctivitis
Hypersensitivity to alcaftadine or any component of the formulation.
Allergic conjunctivitis: Ophthalmic: Instill 1 drop into each eye once daily.
Refer to adult dosing.
Allergic conjunctivitis: Ophthalmic: Children ≥2 years and Adolescents: Refer to adult dosing.
There are no dosage adjustments provided in the manufacturer 's labeling.
There are no dosage adjustments provided in the manufacturer 's labeling.
For topical ophthalmic use only. Contact lenses should be removed prior to application, and may be reinserted 10 minutes after administration. Separate administration of other ophthalmic agents by 5 minutes. Do not insert contacts if eyes are red. Avoid contaminating the applicator tip with affected eye(s).
Store at 15 ‚ °C to 25 ‚ °C (59 ‚ °F to 77 ‚ °F).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic:
Lastacaft: 0.25% (3 mL) [contains benzalkonium chloride, edetate disodium]
There are no known significant interactions.
1% to 10%:
Central nervous system: Headache (<3%)
Ophthalmic: Burning sensation of eyes (<4%), eye irritation (<4%), eye pruritus (<4%), eye redness (<4%), stinging of eyes (<4%)
Respiratory: Nasopharyngitis (<3%)
<1% (Limited to important or life-threatening): Erythema of eyelid, eye discharge, eyelid edema, hypersensitivity, swelling of eye
Special populations:
- Contact lens wearers: Contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lenses prior to administration and wait 10 minutes before reinserting. Not for the treatment of contact lens irritation; do not wear contact lens if eye is red.
Other warnings/precautions:
- Appropriate use: For topical ophthalmic use only. To avoid eye injury and contamination, do not touch dropper tip to eyelids or any surface.
B
Adverse events were not observed in animal reproduction studies. The amount of alcaftadine absorbed systemically following ophthalmic administration is minimal.
Direct H1-receptor antagonist and inhibitor of histamine release from mast cells
Minimal systemic absorption
Non-CYP450 cytosolic enzymes to the active metabolite carboxylic acid
Carboxylic acid: ~2 hours
~40%; Carboxylic acid (metabolite): ~60%
- Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
- Patient may experience headache, burning, stinging, redness, rhinitis, or pharyngitis. Have patient report immediately to prescriber vision changes, eye pain, or severe eye irritation (HCAHPS).
- Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.